Skip to content
CompletedPhase 2

Ayahuasca and Esketamine for Major Depression

NCT07212946 · University of Sao Paulo

Closed to entry
Status
Not accepting participants
Phase 2
Phase
22
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

Double-blind, randomized trial comparing 4 weekly doses of oral ayahuasca and esketamine in patients with major depression.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Beck Depression Inventory

    Measured over 49 days

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 65 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: \- Clinical diagnosis of depressive disorder Exclusion Criteria: \- Presence of psychiatric and other medical comorbidities

Where

1 study site

FacilityCityRegionCountry
Hospital das Clínicas da FMRP-USPRibeirão PretoSão PauloBrazil

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07212946 on ClinicalTrials.gov →

Last updated in the registry 2025-12-29. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits